Press Releases

Year

August 23, 2023

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C.

August 16, 2023

RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis,

August 14, 2023

RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced financial results for the three months ended June 30, 2023, and provided an update on its business review.

August 2, 2023

RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update

-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET -- BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline

July 5, 2023

RVL Pharmaceuticals plc Provides Business Update

BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of

June 15, 2023

RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting

BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the “Rules”) at the

May 11, 2023

RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majority of aesthetic orders in

May 4, 2023

RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update

Conference call to be held Thursday, May 11, 2023, at 8:30 a.m. ET BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride

April 3, 2023

RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards

Selected from 10,000 Entrants BRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”) announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the

March 20, 2023

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update

-- RVLP records exceptional year-over-year growth with UPNEEQ ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 -- -- Full year 2022 UPNEEQ net product sales of $34.2 million, an increase of $26.7

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Investor Relations

Press Releases

Press Releases

Press Releases